Reproducibility of a prediabetes classification in a contemporary population.
Diabetes
Dysglycemia
FPG
HbA1c
Oral glucose tolerance testing
Prediabetes
Journal
Metabolism open
ISSN: 2589-9368
Titre abrégé: Metabol Open
Pays: England
ID NLM: 101767753
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
12
02
2020
accepted:
04
03
2020
entrez:
20
8
2020
pubmed:
20
8
2020
medline:
20
8
2020
Statut:
epublish
Résumé
To assess whether meeting both fasting plasma glucose (FPG) and HbA1c criteria for prediabetes in people at high risk indicates with near certainty the presence of dysglycemia on repeat testing. Observational study using data from Vitamin D and Type 2 Diabetes (D2d) study. HbA1c, FPG were measured at screening visit 1; FPG, HbA1c and 2 h plasma glucose (2hPG) measured at screening visit 2 (a median of 21 days later); participants classified as having normal glucose regulation (all 3 tests in normal range), prediabetes or diabetes (at least 1 of 3 tests in diabetes range). A predictive model was developed to estimate the probability of confirming dysglycemia and for detecting diabetes at screening visit 2 based on values of FPG and HbA1c at screening visit 1. Of 1271 participants who met both FPG and HbA1c criteria for prediabetes at screening visit 1, 98.6% exhibited dysglycemia (defined as prediabetes or diabetes) on repeat testing (84.5% were classified as having prediabetes, 14.1% were reclassified as having diabetes). Of those with diabetes, 62.6% were identified by 2hPG alone. Combined measurement of FPG and HbA1c is a reliable and reproducible measure to identify presence of dysglycemia among people at high risk. A prediction model is provided to help clinicians decide whether an oral glucose tolerance test will provide value in detecting diabetes based on the 2hPG criterion.
Identifiants
pubmed: 32812912
doi: 10.1016/j.metop.2020.100031
pii: S2589-9368(20)30011-6
pii: 100031
pmc: PMC7424833
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100031Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Diabetes Care. 2003 Mar;26(3):645-9
pubmed: 12610015
Diabetes Care. 2018 Aug;41(8):1590-1599
pubmed: 29941495
Diabetes Care. 2017 Feb;40(2):e8-e9
pubmed: 27899488
Diabetes Care. 2010 Oct;33(10):2184-9
pubmed: 20639452
Diabetes Care. 2005 Jan;28(1):138-44
pubmed: 15616247
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
J Clin Endocrinol Metab. 2015 May;100(5):1997-2005
pubmed: 25751104
Diabetes Care. 1997 May;20(5):785-91
pubmed: 9135943
Ann Intern Med. 2018 Aug 7;169(3):156-164
pubmed: 29913486
Diabetes Care. 2010 Jul;33(7):1665-73
pubmed: 20587727
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
BMJ. 1994 May 21;308(6940):1323-8
pubmed: 8019217
Diabetes Care. 2014 Dec;37(12):3227-34
pubmed: 25205139
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
pubmed: 20042772
Diab Vasc Dis Res. 2018 Jan;15(1):46-54
pubmed: 29113512